Lung Cancer News and Research

Latest Lung Cancer News and Research

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.

22 Nov 2011

Study: Vaccine development efforts currently focus on incidence rather than mortality rates

Drug companies currently developing therapeutic cancer vaccines may be determining the cancers they target based on the number of annual cases, not the number of deaths they cause.

22 Nov 2011

New 'triggered imaging' enables physicians to better target tumors during radiosurgery

A new type of "triggered imaging" technology enables University of Alabama at Birmingham physicians to better target tumors during radiosurgery and lessens the risk of injury to surrounding lung tissue.

22 Nov 2011

Researchers identify EGFR protein as therapeutic target for Cushing disease

Cushing disease is a hormone disorder that causes a diverse array of symptoms, including fat accumulation, high blood pressure, osteoporosis, muscle wasting, and ultimately death. It is caused by a tumor in the anterior pituitary gland that results in the secretion of excess amounts of adrenocorticotropic hormone (ACTH). Treatment options are essentially limited to surgical resection. However, tumors commonly recur, meaning that new treatment options are needed.

22 Nov 2011

2011 National Report Card on Lung Cancer notes significant change in grade for early detection

Today, Lung Cancer Alliance (LCA), the leading national support and advocacy voice for those at risk for or living with lung cancer, issued its annual 2011 National Report Card on Lung Cancer, an overall assessment of the nation's response to the continuing high mortality of lung cancer, the leading cause of cancer death.

21 Nov 2011

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

ZIOPHARM Oncology, Inc. announced today the publication of a darinaparsin (Zinapar or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science.

21 Nov 2011

Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib, a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer.

18 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

HVTN debunks top 10 myths about HIV vaccine research

Dec. 1 is World AIDS Day, and in commemoration of the occasion, the HIV Vaccine Trials Network, headquartered at Fred Hutchinson Cancer Research Center, debunks the top 10 myths about HIV vaccine research.

18 Nov 2011

Medicaid officials struggle with surge in long-term care needs

The company's naming of David J. McNichols comes as a consulting firm for the state is evaluating the current system of delivering care to Medicaid and PeachCare beneficiaries in Georgia. WellCare has part of that multibillion-dollar business, along with two other managed care companies. The state pays the three firms a total of more than $2.5 billion a year to serve the Medicaid and PeachCare populations.

18 Nov 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

Gold nanoparticles help detect lung cancer in exhaled breath

The metabolism of lung cancer patients is different than the metabolism of healthy people. And so the molecules that make up cancer patients' exhaled breath are different too.

17 Nov 2011

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.

17 Nov 2011

VHIO, MGHCC sign tumor biomarker agreement

The President of the BBVA Foundation, Francisco Gonz-lez, Jose Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center (MGHCC), and Andr-s de Kelety, Managing Director at the Vall d'Hebr-n Institute of Oncology (VHIO) in Barcelona, yesterday signed the agreement creating the BBVA Foundation Tumor Biomarkers Research Program.

17 Nov 2011

Cancer cells tap into natural recycling system to obtain energy

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that cancer cells tap into a natural recycling system to obtain the energy they need to keep dividing. In a study with potential implications for cancer treatments, Einstein researchers used genetic manipulation to turn off this recycling system within the walls of cells and stop both tumor growth and metastasis.

17 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Silibinin stops spread of lung cancer in mice

Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions and so stopped the spread of these lung cancers, according to a recent study published in the journal Molecular Carcinogenesis.

16 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

Radon exposure may increase risk of non-melanoma skin cancer

A new study published this week suggests that a link may exist between radon exposure and non-melanoma skin cancer.

15 Nov 2011

Women with inflammatory breast cancer now have a chance of treatment

Women with the deadliest and rarest form of breast cancer now have a chance of treatment where once their options were severely limited, thanks to a new discovery by George Mason University researchers.

15 Nov 2011